KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Debt to Equity: 2017-2024

Historic Debt to Equity for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to -$21.79.

  • Amneal Pharmaceuticals' Debt to Equity rose 8.53% to -$23.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.41, marking a year-over-year increase of 8.53%. This contributed to the annual value of -$21.79 for FY2024, which is 117.00% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Debt to Equity of -$21.79 as of FY2024, which was down 117.00% from $128.18 recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Debt to Equity registered a high of $128.18 during FY2023, and its lowest value of -$21.79 during FY2024.
  • For the 3-year period, Amneal Pharmaceuticals' Debt to Equity averaged around $40.27, with its median value being $14.41 (2022).
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 789.24% in 2023, then plummeted by 117.00% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Debt to Equity stood at $8.06 in 2020, then decreased by 7.75% to $7.43 in 2021, then spiked by 93.91% to $14.41 in 2022, then surged by 789.24% to $128.18 in 2023, then slumped by 117.00% to -$21.79 in 2024.